- Home
- BMA vs KRYS Comparison
BMA vs KRYS Comparison
Compare BMA & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMA | KRYS |
|---|---|---|
| Founded | 1966 | 2015 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 9.3B |
| IPO Year | 2006 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BMA | KRYS |
|---|---|---|
| Price | $89.48 | $322.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $99.33 | ★ $297.60 |
| AVG Volume (30 Days) | 209.8K | ★ 609.9K |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 3.62 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $16.25 | $38.74 |
| Revenue Next Year | N/A | $32.53 |
| P/E Ratio | ★ $33.22 | $89.72 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $38.30 | $132.31 |
| 52 Week High | $106.15 | $382.54 |
Technical Indicators
Market Signals| Indicator | BMA | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 42.23 |
| Support Level | $85.80 | $318.87 |
| Resistance Level | $95.02 | $377.89 |
| Average True Range (ATR) | 4.04 | 17.88 |
| MACD | -0.33 | -4.22 |
| Stochastic Oscillator | 26.00 | 35.27 |
Price Performance
Historical ComparisonAbout BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. The company generates the majority of its revenue from Argentina.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.